Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.68M | 7.29M | 3.22M | 40.90M | 128.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.68M | 7.29M | 3.22M | 40.90M | 128.23M |
| Cost of Revenue | 25.48M | 29.74M | 39.17M | 34.30M | 40.45M |
| Gross Profit | -11.80M | -22.45M | -35.95M | 6.60M | 87.78M |
| SG&A Expenses | 18.49M | 21.62M | 28.57M | 21.28M | 19.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.97M | 51.36M | 67.74M | 55.58M | 59.53M |
| Operating Income | -30.29M | -44.07M | -64.51M | -14.68M | 68.70M |
| Income Before Tax | -29.73M | -47.01M | -72.52M | -16.79M | 70.05M |
| Income Tax Expenses | 612.00K | 575.00K | 1.69M | 831.00K | 526.00K |
| Earnings from Continuing Operations | -30.34M | -47.58M | -74.22M | -17.62M | 69.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.34M | -47.58M | -74.22M | -17.62M | 69.52M |
| EBIT | -30.29M | -44.07M | -64.51M | -14.68M | 68.70M |
| EBITDA | -27.78M | -41.61M | -61.68M | -11.86M | 71.44M |
| EPS Basic | -0.69 | -1.11 | -1.74 | -0.41 | 1.63 |
| Normalized Basic EPS | -0.07 | -0.11 | -0.16 | -0.04 | 0.17 |
| EPS Diluted | -0.72 | -1.11 | -1.85 | -0.41 | 1.44 |
| Normalized Diluted EPS | -0.07 | -0.11 | -0.16 | -0.04 | 0.17 |
| Average Basic Shares Outstanding | 264.09M | 257.03M | 255.92M | 255.77M | 255.59M |
| Average Diluted Shares Outstanding | 44.01M | 42.84M | 42.65M | 42.63M | 43.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |